Trials / Completed
CompletedNCT01701362
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Pregabalin (Bid) In Subjects With Post-traumatic Peripheral Neuropathic Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 542 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin | capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization |
| DRUG | placebo | capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2012-10-05
- Last updated
- 2021-01-28
- Results posted
- 2017-06-07
Locations
156 sites across 13 countries: United States, Bulgaria, Canada, Croatia, Denmark, Germany, Hungary, Poland, Puerto Rico, Romania, South Africa, South Korea, Sweden
Source: ClinicalTrials.gov record NCT01701362. Inclusion in this directory is not an endorsement.